Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mainz Biomed NV MYNZ

Healthcare Biotechnology
Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of... see more

Recent & Breaking News (NDAQ:MYNZ)

Mainz Biomed to Attend the JonesTrading 2023 Healthcare Summit 

GlobeNewswire October 5, 2023

Mainz Biomed Announces Live Launch of ColoAlert® with Bioclinica in Romania

GlobeNewswire October 4, 2023

Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology

GlobeNewswire September 27, 2023

Mainz Biomed to Present at the Cantor Fitzgerald Global Healthcare Conference 

GlobeNewswire September 20, 2023

Mainz Biomed's ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 81%

GlobeNewswire September 13, 2023

Mainz Biomed Announces Strategic Partnership with Ärztliches Labor Dr. Buhlmann, Expanding Footprint in German Market

GlobeNewswire September 5, 2023

Mainz Biomed to Present at the H.C. Wainwright Global Investment Conference

GlobeNewswire August 29, 2023

Mainz Biomed Announces Live Launch of ColoAlert® with testDNA Laboratory in Poland

GlobeNewswire August 22, 2023

Mainz Biomed Announces Financial Half Year Results 2023 and Provides Corporate Update

GlobeNewswire August 15, 2023

Mainz Biomed Announces Live Launch of ColoAlert® with Marylebone Laboratory in the United Kingdom

GlobeNewswire August 1, 2023

Mainz Biomed Announces Collaboration with Fugene Genetics in Israel

GlobeNewswire July 18, 2023

Mainz Biomed Secures up to $50M in New Funding

GlobeNewswire June 29, 2023

Mainz Biomed to Attend ESMO World Congress on Gastrointestinal Cancer 2023 in Barcelona, Spain

GlobeNewswire June 28, 2023

Mainz Biomed Expands into Romania Through Partnership with Bioclinica

GlobeNewswire June 20, 2023

Mainz Biomed Expands Commercial Footprint into Poland

GlobeNewswire May 31, 2023

Mainz Biomed Processes First Patients from Colorectal Cancer Screening Campaign Through its Corporate Health Portal in Partnership with Zöeller-Kipper

GlobeNewswire May 24, 2023

Mainz Biomed Announces First Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire May 16, 2023

Mainz Biomed Partners with Microba Life Sciences for the Development of PancAlert

GlobeNewswire May 10, 2023

Mainz Biomed Announces Addition of Eurofins GeLaMed to its Growing Network of Lab Partners

GlobeNewswire May 3, 2023

Mainz Biomed to Participate in Digestive Disease Week 2023

GlobeNewswire May 1, 2023